MARTINSRIED, MUNCHEN, GERMANY--(Marketwire - May 04, 2010) - MorphoSys AG / MorphoSys to Present at Three Upcoming Investor Conferences processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR) (Prime Standard Segment, TecDAX) announced today that its management will give company presentations at three upcoming investor conferences:
Deutsche Bank's 35th Annual Health Care Conference Date: May 3-5, 2010 Venue: Boston, USA Presenter: Dr. Simon Moroney, CEO of MorphoSys AG BioEquity Europe 2010 Date: May 19-20, 2010 Venue: Zurich, Switzerland Presenter: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations Bank of America Merrill Lynch Biotech, Medtech & Mid-cap Pharma 1-1 Conference Date: May 25-26, 2010 Venue: London, UK Presenter: Dr. Simon Moroney, CEO of MorphoSys AG
The PDF versions and, if available, live and archived webcasts of the presentations will be provided at www.morphosys.com.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel
antibodies for therapeutic, diagnostic and research applications. The
Company's HuCAL technology is one of the most powerful methods available
for generating fully human antibodies. By successfully applying this and
other proprietary technologies, MorphoSys has become a leader in the field
of therapeutic antibodies, one of the fastest-growing drug classes in human
health-care. Through its alliances with some of the world's leading
pharmaceutical companies, MorphoSys has created a pipeline of more than 60
drug candidates. The Company is expanding its drug pipeline by adding new
partnered programs, and by building a portfolio of fully-owned therapeutic
antibodies. For its proprietary portfolio, the Company is focused on the
areas of oncology and inflammation. Its most advanced program MOR103, a
first-in-class, fully human antibody against GM-CSF, is currently tested in
a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business
unit AbD Serotec, MorphoSys is expanding the reach of its technologies in
the diagnostics and research markets. MorphoSys is headquartered in Munich,
Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR".
For further information, visit http://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys AG.
This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of the
date of this release and involve risks and uncertainties. Should actual
conditions differ from the Company's assumptions, actual results and
actions may differ from those anticipated. MorphoSys does not intend to
update any of these forward-looking statements as far as the wording of
the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors@morphosys.com
[HUG#1411528]
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,Prime All Share,CDAX,TECH All
Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Conference Announcement: http://hugin.info/130295/R/1411528/363931.pdf
